NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 11 04:00PM ET
0.9000
Dollar change
+0.0099
Percentage change
1.11
%
Index- P/E- EPS (ttm)-1.65 Insider Own6.63% Shs Outstand4.34M Perf Week5.88%
Market Cap3.91M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.05M Perf Month-10.00%
Enterprise Value-0.17M PEG- EPS next Q- Inst Own6.71% Short Float0.43% Perf Quarter2.16%
Income-6.06M P/S390.60 EPS this Y- Inst Trans-0.61% Short Ratio0.13 Perf Half Y-67.51%
Sales0.01M P/B0.69 EPS next Y- ROA-101.78% Short Interest0.02M Perf YTD-60.00%
Book/sh1.31 P/C0.92 EPS next 5Y- ROE-109.58% 52W High9.00 -90.00% Perf Year-19.64%
Cash/sh0.97 P/FCF- EPS past 3/5Y-2.65% -21.07% ROIC-101.23% 52W Low0.74 21.84% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- -42.40% Gross Margin-6262.11% Volatility9.09% 8.60% Perf 5Y-
Dividend TTM- EV/Sales-17.40 EPS Y/Y TTM47.22% Oper. Margin-97344.76% ATR (14)0.07 Perf 10Y-
Dividend Ex-Date- Quick Ratio7.13 Sales Y/Y TTM-95.95% Profit Margin-95739.17% RSI (14)52.17 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio7.27 EPS Q/Q48.77% SMA207.14% Beta1.64 Target Price3.00
Payout- Debt/Eq0.07 Sales Q/Q-98.28% SMA50-4.91% Rel Volume1.58 Prev Close0.89
Employees19 LT Debt/Eq0.05 Earnings- SMA200-41.50% Avg Volume133.44K Price0.90
IPOJul 21, 2022 Option/ShortNo / Yes EPS/Sales Surpr.-37.84% -100.00% Trades Volume210,908 Change1.11%
Date Action Analyst Rating Change Price Target Change
Mar-31-25Initiated H.C. Wainwright Buy $3
Mar-31-25 02:57PM
Mar-18-25 07:30AM
Mar-13-25 07:30AM
Mar-05-25 07:30AM
Feb-25-25 07:00AM
06:45AM Loading…
06:45AM
Jan-14-25 09:41AM
Jan-13-25 09:20AM
Dec-17-24 07:30AM
Dec-10-24 07:30AM
Oct-23-24 07:30AM
07:15AM
Sep-16-24 08:30AM
08:30AM
Sep-09-24 08:00AM
09:03AM Loading…
Aug-29-24 09:03AM
Aug-28-24 07:30AM
07:16AM
Aug-23-24 04:09PM
Aug-21-24 09:30PM
10:20AM
Jun-07-24 08:31AM
07:22AM
Jun-06-24 07:55AM
07:38AM
Apr-25-24 09:45AM
08:00AM
Apr-16-24 07:30AM
Mar-15-24 04:30PM
Dec-21-23 07:30AM
07:30AM Loading…
Dec-18-23 07:30AM
Dec-14-23 07:30AM
Sep-21-23 12:21PM
Sep-12-23 07:30AM
Sep-01-23 07:30AM
Aug-03-23 07:30AM
Jul-18-23 07:30AM
Jun-21-23 12:14PM
Jun-14-23 07:30AM
May-05-23 08:19AM
May-04-23 07:30AM
Apr-19-23 07:30AM
Mar-10-23 05:17PM
Mar-08-23 08:55AM
Mar-07-23 09:15AM
07:30AM
Feb-16-23 07:12AM
Feb-07-23 10:07AM
08:30AM
Feb-06-23 04:05PM
Feb-02-23 07:30AM
Jan-04-23 07:30AM
07:00AM
Dec-13-22 03:52PM
Dec-06-22 07:30AM
Nov-15-22 07:30AM
Nov-08-22 04:30PM
Nov-04-22 07:30AM
Nov-03-22 11:02AM
07:30AM
07:10AM
Oct-26-22 07:30AM
Sep-22-22 07:30AM
Sep-20-22 07:30AM
07:15AM
Sep-12-22 09:17AM
07:00AM
Sep-06-22 04:00PM
Aug-16-22 07:30AM
Jul-29-22 06:40PM
Jul-26-22 08:00AM
Jul-21-22 10:33AM
Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The company was founded by James Foster and Cameron Shaw in 2013 and is headquartered in London, the United Kingdom.